Novartis' drug Adakveo, or crizanlizumab-tmca, was approved by the FDA as a treatment for patients aged 16 and older with sickle cell disease patients to lessen the frequency of vaso-occlusive crisis.
Sickle cell disease drug crizanlizumab by Novartis gains FDA approval
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.